Acro Biomedical Co., Ltd.
ACBM · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -0.01 | 0.01 | 0.00 |
| FCF Yield | -129.47% | -223.61% | -37.53% | -37.99% |
| EV / EBITDA | -0.33 | -21.84 | -25.26 | -22.40 |
| Quality | ||||
| ROIC | 26.61% | 21.88% | 6.47% | 6.64% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 17.78% |
| Cash Conversion Ratio | 0.02 | -0.03 | 2.19 | -0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 42.10% | -317.11% | 1.21% | 0.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.04 | -18.75 | -18.54 | -16.06 |
| Interest Coverage | -42.47 | -6.99 | -6.54 | -7.86 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | -46.96 |